Gastrointestinal side effect profile due to the use of alendronate in the treatment of osteoporosis

Date
2003
Author
Alper, S
Aki, S
Eskiyurt, N
Akarirmak, U
Tuzun, F
Eryavuz, M
Arpacioglu, O
Atalay, F
Kavuncu, V
Kokino, S
Kuru, O
Nas, K
Ozerbil, O
Savas, G
Sendur, OF
Soy, D
Akyuz, G
Metadata
Show full item record
Abstract
The aim of our study was to evaluate the upper gastrointestinal (GI) tract side effect profile in 759 female patients that had taken alendronate (10 mg/day), for at least 6 months, for the treatment of osteoporosis, in relation to the safety of alendronate and the compliance of patients to its absorption rules.
URI
http://hdl.handle.net/20.500.12627/154191
https://doi.org/10.3349/ymj.2003.44.6.961
Collections